Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS.

Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.

2.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B.

Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.

3.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM.

Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.

4.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Fitz NF, Cronican AA, Lefterov I, Koldamova R.

Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.

5.

Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA.

Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.

6.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

7.

Medicine. Old drug, new hope for Alzheimer's disease.

Strittmatter WJ.

Science. 2012 Mar 23;335(6075):1447-8. doi: 10.1126/science.1220725. No abstract available.

PMID:
22442467
8.

ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Corona AW, Kodoma N, Casali BT, Landreth GE.

J Neuroimmune Pharmacol. 2016 Mar;11(1):61-72. doi: 10.1007/s11481-015-9627-8. Epub 2015 Jul 15.

PMID:
26175148
9.

Preclinical success against Alzheimer's disease with an old drug.

LaFerla FM.

N Engl J Med. 2012 Aug 9;367(6):570-2. doi: 10.1056/NEJMcibr1204890. No abstract available.

PMID:
22873540
10.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

11.

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.

Rosenthal J, Belfort G, Isaacson D.

PLoS One. 2016 Apr 13;11(4):e0153150. doi: 10.1371/journal.pone.0153150. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0156474.

12.

ApoE: the link between Alzheimer's-related glucose hypometabolism and Aβ deposition?

Patil SP, Ballard R, Sanchez S, Osborn J, Santangelo D Jr.

Med Hypotheses. 2012 Apr;78(4):494-6. doi: 10.1016/j.mehy.2012.01.015. Epub 2012 Jan 28.

PMID:
22285195
13.

Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller JK, Zaccheo D, Gambetti P, Tabaton M.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15598-602.

14.

Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.

Bachmeier C, Beaulieu-Abdelahad D, Crawford F, Mullan M, Paris D.

J Mol Neurosci. 2013 Feb;49(2):270-6. doi: 10.1007/s12031-012-9866-6. Epub 2012 Aug 14.

PMID:
22890420
15.

Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.

Kuntz M, Candela P, Saint-Pol J, Lamartinière Y, Boucau MC, Sevin E, Fenart L, Gosselet F.

J Alzheimers Dis. 2015;48(3):849-62. doi: 10.3233/JAD-150469.

PMID:
26402114
16.

Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.

Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S.

J Neurochem. 2004 Aug;90(4):1011-8.

17.

Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.

Tayler H, Fraser T, Miners JS, Kehoe PG, Love S.

J Alzheimers Dis. 2010;22(4):1363-73. doi: 10.3233/JAD-2010-101368.

PMID:
20930272
18.

Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM.

Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1211-6. Epub 2005 Jan 18.

19.

Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.

Bonet-Costa V, Herranz-Pérez V, Blanco-Gandía M, Mas-Bargues C, Inglés M, Garcia-Tarraga P, Rodriguez-Arias M, Miñarro J, Borras C, Garcia-Verdugo JM, Viña J.

J Alzheimers Dis. 2016;51(3):701-11. doi: 10.3233/JAD-151020.

PMID:
26890773
20.

Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.

Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG.

J Neurosci. 2004 Apr 14;24(15):3801-9.

Supplemental Content

Support Center